{"id":"W2116236442","doi":"10.1186/bcr3484","title":"Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer","year":2013,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":185,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; Sunnybrook Health Science Centre","funders":"American Society of Clinical Oncology; AstraZeneca","keywords":"Medicine; Olaparib; Neutropenia; Tolerability; Internal medicine; Febrile neutropenia; PARP inhibitor; Metastatic breast cancer; Taxane; Oncology; Breast cancer; Regimen; Cohort; Adverse effect; Surgery; Chemotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008011642,0.001291899,0.001469151,0.0002968945,0.0003706997,0.001018405,0.0008877736,0.000882083,0.003996843],"category_scores_gemma":[0.0005687724,0.0004568632,0.00073498,0.0003202488,0.0005720052,0.0004805954,0.0002906467,0.002810621,0.0007807227],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008416577,"about_ca_system_score_gemma":0.001431569,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007635222,"about_ca_topic_score_gemma":0.00261396,"domain_scores_codex":[0.9997907,0.0000792352,0.00001145716,0.00004313562,0.00002321624,0.00005226848],"domain_scores_gemma":[0.9994965,0.00006572183,0.0001189682,0.00003656216,0.00002442415,0.0002579071],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7153707,0.08952345,0.01064165,0.001174579,0.001352985,0.0004316132,0.0003042819,0.00217393,0.04273774,0.0002335984,0.00580459,0.1302509],"study_design_scores_gemma":[0.6767766,0.3054584,0.009318034,0.0000526871,0.0003602334,0.0003959719,0.00003727761,0.0009593634,0.003964256,0.0001166964,0.002537751,0.00002268076],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919122,0.002172393,0.0004334151,0.0005101127,0.0001268508,0.002042942,0.0009681682,0.00008743331,0.001746326],"genre_scores_gemma":[0.9888356,0.001972297,0.001210124,0.0007679745,0.000219348,0.002301252,0.002410321,0.0000256644,0.002257408],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003996843,"threshold_uncertainty_score":0.01337081,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08670294013995589,"score_gpt":0.4172623707952946,"score_spread":0.3305594306553387,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}